Drugs / ADSCs
ADSCs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02813512 | Oct 2017 → Nov 2018 | ischemic stroke | Gwo Xi Stem Cell Applied Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02297867 | Jul 2015 → Dec 2017 | cirrhosis of liver | Gwo Xi Stem Cell Applied Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02161744 | Oct 2013 → Oct 2018 | chronic obstructive pulmonary disease | Arkansas Heart Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01771913 Comparator | Mar 2012 → Sep 2014 | — | University of Sao Paulo | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02161744 ↗ |
| Known as | aADSC | “autologous adipose derived stem cells (aADSC) administered intravenously” NCT02161744 ↗ |
| Known as | adipose-derived stem (stromal) cells | “autologous adipose-derived stem (stromal) cells (ASCs) are used in combination with lipoinjection.” PMID 17763894 ↗ Sep 2007 |
| Known as | ASCs | “autologous adipose-derived stem (stromal) cells (ASCs) are used in combination with lipoinjection.” PMID 17763894 ↗ Sep 2007 |
| Known as | GXNPC1 | “This Phase I open-label study was conducted to demonstrate the safety and efficacy of autologous adipose-derived stem cells (GXNPC1) in chronic stroke.” PMID 34644444 ↗ Oct 2021 |
| Modality | Cell therapy | “autologous adipose-derived stem (stromal) cells (ASCs) are used in combination with lipoinjection.” PMID 17763894 ↗ Sep 2007 |
| Route | Intravenous | “administered intravenously” NCT02161744 ↗ |